title: Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinoside and daunorubicin.
authors.forename: J W
authors.initials: JW
authors.lastname: Taub
authors.forename: M L
authors.initials: ML
authors.lastname: Stout
authors.forename: S A
authors.initials: SA
authors.lastname: Buck
authors.forename: X
authors.initials: X
authors.lastname: Huang
authors.forename: R A
authors.initials: RA
authors.lastname: Vega
authors.forename: D L
authors.initials: DL
authors.lastname: Becton
authors.forename: Y
authors.initials: Y
authors.lastname: Ravindranath
mesh_terms: D000208:Acute Disease; D001853:Bone Marrow / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002648:Child; D003561:Cytarabine / Q000627:therapeutic use*; D003630:Daunorubicin / Q000627:therapeutic use*; D004314:Down Syndrome / Q000150:complications / Q000473:pathology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications / Q000188:drug therapy*; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D003561:Cytarabine; D003630:Daunorubicin